Srishti Raj1, Basavraj Tigari1, T T Faisal1, Natasha Gautam1, Sushmita Kaushik1, Parul Ichhpujani2, Surinder S Pandav3, Jagat Ram1. 1. Department of Ophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. 2. Department of Ophthalmology, Government Medical College and Hospital, Sector 32, Chandigarh, India. 3. Department of Ophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. sspandav@yahoo.com.
Abstract
BACKGROUND: To study the role of selective laser trabeculoplasty (SLT) in intraocular pressure (IOP) reduction in post-laser iridotomy primary angle-closure disease patients with inadequately controlled IOP. METHODS: In this prospective cross-sectional study, 34 patients with primary angle-closure disease with post-laser iridotomy open angles up to at least 180° were recruited. Following SLT, patients were examined at 1 day, 1 week, 1 and 3 months, 6 months and 1 year post SLT. RESULTS: Data of 34 patients (34 eyes; 8 males and 26 females), with a mean age of 57.80 ± 6.44 years, were analysed. The reduction in IOP at each follow-up visit was significant (p < 0.001). The maximum reduction in IOP was noticed on post-laser day 1 and the least reduction was noticed 1 week post laser. Post-SLT range of IOP reduction varied from 9 to 46% at 1 year, which indicates the variability of a response to SLT. Mean IOP in both primary angle closure (PAC) and primary angle closure glaucoma (PACG) groups was comparable at all visits except at post-SLT week 1 when IOP in the PACG group was significantly higher than that in the PAC group (p = 0.035). None of the patients complained of pain and/or discomfort or had any clinically significant anterior segment inflammation on any of the follow-up visits. None of the patients underwent repeat SLT or surgery. The mean pre-SLT and post-SLT visual field index at 1-year follow-up was 95.47 ± 3.58 and 95.90 ± 4.13, respectively, which was not significant (p = 0.84). CONCLUSIONS: High baseline IOP significantly correlated with reduction in IOP. Our results suggest that SLT is a safe, cost-effective modality for reducing IOP in primary angle-closure disease with patent laser iridotomy with a visible trabecular meshwork.
BACKGROUND: To study the role of selective laser trabeculoplasty (SLT) in intraocular pressure (IOP) reduction in post-laser iridotomy primary angle-closure disease patients with inadequately controlled IOP. METHODS: In this prospective cross-sectional study, 34 patients with primary angle-closure disease with post-laser iridotomy open angles up to at least 180° were recruited. Following SLT, patients were examined at 1 day, 1 week, 1 and 3 months, 6 months and 1 year post SLT. RESULTS: Data of 34 patients (34 eyes; 8 males and 26 females), with a mean age of 57.80 ± 6.44 years, were analysed. The reduction in IOP at each follow-up visit was significant (p < 0.001). The maximum reduction in IOP was noticed on post-laser day 1 and the least reduction was noticed 1 week post laser. Post-SLT range of IOP reduction varied from 9 to 46% at 1 year, which indicates the variability of a response to SLT. Mean IOP in both primary angle closure (PAC) and primary angle closure glaucoma (PACG) groups was comparable at all visits except at post-SLT week 1 when IOP in the PACG group was significantly higher than that in the PAC group (p = 0.035). None of the patients complained of pain and/or discomfort or had any clinically significant anterior segment inflammation on any of the follow-up visits. None of the patients underwent repeat SLT or surgery. The mean pre-SLT and post-SLT visual field index at 1-year follow-up was 95.47 ± 3.58 and 95.90 ± 4.13, respectively, which was not significant (p = 0.84). CONCLUSIONS: High baseline IOP significantly correlated with reduction in IOP. Our results suggest that SLT is a safe, cost-effective modality for reducing IOP in primary angle-closure disease with patent laser iridotomy with a visible trabecular meshwork.
Authors: Augusto Azuara-Blanco; Jennifer Burr; Craig Ramsay; David Cooper; Paul J Foster; David S Friedman; Graham Scotland; Mehdi Javanbakht; Claire Cochrane; John Norrie Journal: Lancet Date: 2016-10-01 Impact factor: 79.321
Authors: Arun Narayanaswamy; Christopher K Leung; Donny V Istiantoro; Shamira A Perera; Ching-Lin Ho; Monisha E Nongpiur; Mani Baskaran; Hla M Htoon; Tina T Wong; David Goh; Daniel H Su; Michael Belkin; Tin Aung Journal: JAMA Ophthalmol Date: 2015-02 Impact factor: 7.389
Authors: Ching Lin Ho; Jimmy S M Lai; Mario V Aquino; Prin Rojanapongpun; Hon Tym Wong; Ma Cecilia Aquino; Yariv Gerber; Michael Belkin; Yaniv Barkana Journal: J Glaucoma Date: 2009-09 Impact factor: 2.503
Authors: Nathan Radcliffe; Gus Gazzard; Thomas Samuelson; Peng Khaw; Xinghuai Sun; Tin Aung; Dennis Lam; Kuldev Singh; L Jay Katz; Michael Aronov; Zachary Sacks; Yoram Solberg; Richard Lindstrom; Michael Belkin Journal: J Glaucoma Date: 2022-06-15 Impact factor: 2.290